Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine chemoprophylaxis for SARS-CoV-2 infection in healthcare professionals
2020-001421-31Phase 4Active
- Sponsor
- Sociedad Española de Farmacia Hospitalaria
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Sociedad Española de Farmacia Hospitalaria. Primary endpoint: Diagnosis of SARS-CoV-2 COVID-19 infection. Started Apr 2020; status: active.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001421-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001421-31.